Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer

Web Exclusives - Breast Cancer, FDA Approvals, News & Updates, Web Exclusive

On March 13, 2017, ribociclib (Kisqali; Novartis) became the third CDK4/CDK6 inhibitor to be approved by the FDA. The FDA approved ribociclib, in combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. Ribociclib received a breakthrough therapy designation and was approved under the FDA’s priority review process.

This approval was based on the phase 3 MONALEESA-2 clinical trial that included 668 treatment-naïve postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The patients were randomized to ribociclib plus letrozole or placebo plus letrozole.

Ribociclib plus letrozole reduced mortality risk by 44%. The median progression-free survival (PFS) was not reached in the ribociclib plus letrozole combination (95% CI, 19.3-not reached) and was 14.7 months with letrozole and placebo (P <.0001). The ORR was 52.7% versus 37.1%, respectively. In another analysis with an 11-month follow-up, the PFS was 25.3 months with the addition of ribociclib and 16 months with letrozole alone.

“These results affirm that combination therapy with a CDK4/6 inhibitor like ribociclib and an aromatase inhibitor should be a new standard of care for initial treatment of HR+ advanced breast cancer,” said Gabriel N. Hortobagyi, MD, Professor of Medicine, Department of Breast Medical Oncology, M.D. Anderson Cancer Center, Houston, and principal investigator of MONALEESA-2.

The most common all-grade adverse reactions with ribociclib plus letrozole included neutropenia (75%), leukopenia (33%), headache (22%), back pain (20%), nausea (52%), diarrhea (35%), vomiting (29%), constipation (25%), alopecia (33%), and fatigue (37%). Dose reductions because of adverse reactions were 45% with the active combination versus 3% with letrozole and placebo. Permanent discontinuation of therapy was reported in 7% of patients versus 2%, respectively.

Related Items
Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 20, 2018 in FDA Approvals, News & Updates
Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 20, 2018 in FDA Approvals, News & Updates
Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 20, 2018 in FDA Approvals, News & Updates
Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation
Loretta Fala
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 20, 2018 in FDA Approvals, News & Updates
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh
March 2018, Vol 11, Ninth Annual Payers' Guide published on April 20, 2018 in FDA Approvals, News & Updates
Last modified: April 28, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME